Please ensure Javascript is enabled for purposes of website accessibility

Market-Moving News Is on Tap for Seattle Genetics

By Todd Campbell - Dec 4, 2017 at 7:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Full study results will be released at a high-profile conference this month.

Seattle Genetics (SGEN -0.74%) Adcetris is already a successful drug with global sales of about $600 million, but sales could climb even higher if the Food and Drug Administration approves its use in frontline Hodgkin's lymphoma. The company recently filed for a label expansion in that indication, and it will unveil comprehensive data from the pivotal study supporting its application soon. If the data is positive, it could add confidence that the FDA will give it a green light. Is now a good time to buy this biotech stock in portfolios?

What's going on?

The opportunity associated with an approval in frontline Hodgkin lymphoma is big, so investors should pay attention when Seattle Genetics trial investigators explain their findings at the American Society of Hematology (ASH) conference on Dec. 10.

A man in wearing a dress shirt and tie listens through a wall using a styrofoam cup pressed against his ear.


If the data is solid, then an eventual FDA approval could mark the first significant change to frontline advanced Hodgkin lymphoma treatment in nearly forty years. Currently, treatment consists of four chemotherapies, including bleomycin, which can cause life-threatening lung damage.

We don't have all the study data yet, but the data we've seen so far is encouraging. Replacing bleomycin with Adcetris reduced the risk of worsening cancer, death, or need for additional cancer treatment by 23%, and it improved disease-free survival by about 5% at the two-year mark. As long as the full data set doesn't raise any concerns, this top-line data suggests Adcetris could eventually become part of the standard-of-care regimen in stage 3 and 4 patients.

An approval in the frontline setting could significantly boost Adcetris' addressable patient pool because it's only currently approved for use in advanced Hodgkin's lymphoma patients who are refractory or relapsing following other treatments. Overall, there are about 62,000 new cases of Hodgkin lymphoma diagnosed per year globally and roughly 30% don't respond to initial treatment or they relapse within the first two years. 

The financial tailwind from an approval depends on prescription volume, but because Adcetris is a pricey drug, it may not take a lot of new patients to make an impact. The actual cost per patient will depend on each patient's weight, but estimates are that it will fetch between $100,000 to $120,000 per patient in the frontline setting.

What's next

Seattle Genetics is already calling on doctors who treat advanced Hodgkin lymphoma patients, so selling it as a frontline therapy should be pretty simple. The FDA hasn't said when a decision could be made and there's no guarantee of an OK, but we should have a better idea of the likelihood of a green light following the ASH presentation.

If sales begin to roll in from the frontline indication, it would be welcome news for investors because Seattle Genetics is still losing money. It commercializes Adcetris in the U.S., but it only collects royalties on sales overseas by its collaboration partner, Takeda. Between U.S. sales, collaboration revenue, and royalties, Seattle Genetics brought in $353 million in revenue during the first nine months, but its operating costs for the period total $503 million.

Winning approval in the frontline setting could finally put the company in a position to close the gap and get into the black but, again, a lot will depend on what the company says at ASH. The potential for disappointing data makes buying Seattle Genetics right now a bit risky, but given the opportunity and Adcetris' success so far, it might make sense for risk-tolerant growth investors. 

Todd Campbell has no position in any of the stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool recommends Seattle Genetics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Seagen Inc. Stock Quote
Seagen Inc.
$169.25 (-0.74%) $-1.26
Takeda Pharmaceutical Company Limited Stock Quote
Takeda Pharmaceutical Company Limited
$28.11 (-1.18%) $0.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.